CX3CR1 and sarcoma: An immune suppressive myeloid population defined as CX3CR1+CD206+ may strongly influence the outcome of the response to anti-PD-1 therapy since tumor-CX3CR1+CD206+ myeloid cells were reduced after response to anti-PD-1 in a T3 sarcoma mouse model (10).